GSK 257049

Drug Profile

GSK 257049

Alternative Names: 257049; CSP-HBsAg; CSP-HBsAg/SBAS2-GlaxoSmithKline; FSV 1; FSV-1-malaria-vaccine-GlaxoSmithKline; GSK Biologicals' malaria vaccine 257049; Malaria vaccine 257049; Mosquirix; Plasmodium falciparum malaria vaccine 257049; Profilam; QS-21 containing malaria vaccine - Agenus/GlaxoSmithKline; RTS; RTS,S; RTS,S/AS; RTS,S/AS01; RTS,S/AS02; RTS,S/AS02A; S/AS01E; SB 257049

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Malaria Vaccine Initiative; University of Oxford
  • Class Antimalarials; Parasitic vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Falciparum malaria

Most Recent Events

  • 19 Jun 2017 GlaxoSmithKline initiates a phase II trial for Falciparum malaria (In volunteers, Prevention) in USA (NCT03162614)
  • 25 May 2017 GlaxoSmithKline plans a phase II trial for Falciparum malaria (In volunteers, Prevention) in USA (NCT03162614)
  • 10 May 2017 GlaxoSmithKline initiates a phase III trial for Falciparum malaria (Prevention, In infants) in Ghana (IM) (NCT02699099)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top